COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers
Some Hematologists Report Having Problems Scheduling Cell Therapy
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.
You may also be interested in...
In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private.
The company plans to make a new EUA request prior to filing a BLA, but does not yet have a specific timeline. Meanwhile, it has been preparing for the drug’s distribution as a COVID-19 treatment.
Fresenius Kabi has reported positive Phase I data for its MSB11456 proposed tocilizumab biosimilar rival to Actemra/Ro-Actemra, against the backdrop of shortages for the brand which is being used in some regions to treat COVID-19.